RxDoctor Payments DataLook up a doctor →

Hisham Alrefai, MD

Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1811962350

Payments from drug & device makers

$720,023in general payments, 2019–2025

Across 2,474 payments — averaging $291.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$245K
  • Insulet Corporation$121K
  • AstraZeneca$81K
  • Bayer$73K
  • Amgen$66K
  • Corcept Therapeutics$51K
  • plus $83K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk577$245,335
Insulet Corporation198$120,990
AstraZeneca(2 entities)203$81,460
Bayer143$72,525
Amgen(2 entities)133$65,702
Corcept Therapeutics163$50,869
Amarin Pharma, Inc.139$47,625
Valeritas, Inc.30$14,882
Medtronic(2 entities)127$4,020
Cequr Corporation5$2,523
Tandem Diabetes Care, Inc.12$2,027
Boehringer Ingelheim77$1,309
Esperion Therapeutics, Inc.61$904
AbbVie53$873
Xeris Pharmaceuticals, Inc.43$760
IBSA Pharma Inc.51$744
Novartis60$693
Amneal Pharmaceuticals LLC44$632
Antares Pharma, Inc.38$590
Dexcom, Inc.35$539
Recordati_rare_diseases_inc.33$475
Merck30$432
Pfizer21$390
Mannkind Corporation22$369
Chiesi USA, Inc.4$344
Abbott19$338
Halozyme Inc8$302
Kyowa Kirin, Inc.12$233
Nestle Healthcare Nutrition Inc.9$204
Tolmar, Inc.25$190
Zealand Pharma US, Inc.11$166
Shire North American Group Inc9$132
Ascendis Pharma Endocrinology Inc7$131
Alfasigma USA, Inc.6$123
Clarus Therapeutics Inc.8$120
Teleflex LLC2$106
Amryt Pharma Holdings Ltd7$104
Globus Medical4$88
Ultragenyx Pharmaceutical Inc.3$67
Idorsia Pharmaceuticals US Inc3$55
GRT US Holding, Inc.3$53
Kowa Pharmaceuticals America, Inc.4$53
Radius Health, Inc.3$49
Nevro Corp.2$45
Vistapharm, Inc.3$45
Ascensia Diabetes Care US Inc.2$43
EUSA Pharma (US) LLC3$39
Verity Pharmaceuticals Inc.2$39
Azurity Pharmaceuticals, Inc.2$36
Amphastar Pharmaceuticals, Inc.2$33
Currax Pharmaceuticals LLC2$30
Lilly USA, LLC1$22
Neurocrine Biosciences, Inc.1$21
Senseonics, Incorporated1$19
Takeda Pharmaceuticals U.S.A., Inc.1$18
Rhythm Pharmaceuticals, Inc.1$18
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$18
GSK1$15
Lifescan, Inc.1$15
Vifor Pharma, Inc.1$15

How this compares

$720,023 in reported general payments places this provider in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky →

Medicare billing

Part B allowed, 2024
$125,869
Medicare patients
616
Services billed
1,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Louisville

See the full list for Kentucky →

Where these figures come from

Is this you, or does something look wrong? →